Long-Term OPC-34712 Safety as Maintenance Treatment for Schizophrenia
About this title
Read the official source — NCT01397786Researchers studied OPC-34712, tracking side effects to assess long-term safety and tolerability in adults with schizophrenia.
Understand this study
What did researchers investigate?
Researchers studied OPC-34712, tracking side effects to assess long-term safety and tolerability in adults with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Birmingham and 147 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 1,044
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Canada, Colombia, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01397786
- Official title
Show the full official title
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Birmingham, United States · Little Rock, United States · Springdale, United States
126 more locations
- Anaheim, United States
- Cerritos, United States
- Escondido, United States
- Garden Grove, United States
- Glendale, United States
- Long Beach, United States
- National City, United States
- Oakland, United States
- Oceanside, United States
- Pico Rivera, United States
- San Diego, United States
- Torrance, United States
- Washington D.C., United States
- Bradenton, United States
- Leesburg, United States
- Maitland, United States
- Miami, United States
- Miami Springs, United States
- North Miami, United States
- Tampa, United States
- Chicago, United States
- Hoffman Estates, United States
- Joliet, United States
- Oak Brook, United States
- Overland Park, United States
- Lake Charles, United States
- Shreveport, United States
- Flowood, United States
- Saint Charles, United States
- St Louis, United States
- Las Vegas, United States
- Buffalo, United States
- Cedarhurst, United States
- Jamaica, United States
- Rochester, United States
- Staten Island, United States
- Dayton, United States
- Allentown, United States
- Norristown, United States
- Charleston, United States
- Memphis, United States
- Austin, United States
- Dallas, United States
- Houston, United States
- Richmond, United States
- Kirkland, United States
- Burlington, Canada
- Chatham, Canada
- Barranquilla, Colombia
- Bello, Colombia
- Bogotá, Colombia
- Pereira, Colombia
- Rijeka, Croatia
- Zagreb, Croatia
- Fujisawa-shi, Japan
- Kumamoto, Japan
- Kunigami-gun, Japan
- Sakai-shi, Japan
- Daugavpils, Latvia
- Jelgava, Latvia
- Liepāja, Latvia
- Riga, Latvia
- Strenči, Latvia
- Kota Bharu, Malaysia
- Kuala Lumpur, Malaysia
- Kajang, Malaysia
- Ipoh, Malaysia
- Jalan Greentown, Malaysia
- Sabak Bernam, Malaysia
- Col. Florida, Mexico
- Monterrey, Mexico
- San Luis Potosí City, Mexico
- Cebu City, Philippines
- Davao City, Philippines
- Manila, Philippines
- Choroszcz, Poland
- Gdansk, Poland
- Lodz, Poland
- San Juan, Puerto Rico
- Arad, Romania
- Brasov, Romania
- Bucharest, Romania
- Cluj-Napoca, Romania
- Craiova, Romania
- Focşani, Romania
- Iași, Romania
- Piteşti, Romania
- Targoviste, Romania
- Arkhangelsk, Russia
- Moscow, Russia
- Moscow Region, Russia
- Nizhny Novgorod, Russia
- Petrozavodsk, Russia
- Saint Petersburg, Russia
- Samara, Russia
- Saratov, Russia
- Tomsk, Russia
- Village Nikolskoe, Russia
- Belgrade, Serbia
- Kragujevac, Serbia
- Novi Kneževac, Serbia
- Novi Sad, Serbia
- Bratislava, Slovakia
- Michalovce, Slovakia
- Rimavská Sobota, Slovakia
- Rožňava, Slovakia
- Incheon, South Korea
- Seoul, South Korea
- Kashsiung, Taiwan
- New Taipei City, Taiwan
- Taipei, Taiwan
- Taoyuan County, Taiwan
- Diyarbakır, Türkiye
- Kocaeli, Türkiye
- Chernihiv, Ukraine
- Dnipropetrovsk, Ukraine
- Hlevakha, Ukraine
- Kharkiv, Ukraine
- Kherson, Vil. Stepanivka, Ukraine
- Kyiv, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Simferopol, Ukraine
- Vinnytsia, Ukraine
- Russia
- Türkiye
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers studied OPC-34712, tracking side effects to assess long-term safety and tolerability in adults with schizophrenia.
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including OPC-34712.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
